JAMA Netw Open

SGLT2 inhibitors tied to reduced cardiorenal events in patients with T2DM and cirrhosis

February 24, 2026

A nationwide Taiwanese cohort study of 24,259 patients with type 2 diabetes and liver cirrhosis found that SGLT2 inhibitor use was associated with significantly lower risks of adverse outcomes compared with DPP-4 inhibitors. Over a median 2.3-year follow-up, SGLT2 inhibitor users had 66% lower risk of end-stage kidney disease (hazard ratio [HR], 0.34), 34% lower risk of acute kidney injury (HR, 0.66), and 33% lower risk of major adverse cardiovascular events (HR, 0.67). Additionally, SGLT2 inhibitor use was associated with reduced all-cause mortality (HR, 0.58) and hepatic decompensation (HR, 0.65).

Clinical takeaway: Consider SGLT2 inhibitors as a preferred glucose-lowering option in patients with type 2 diabetes and cirrhosis when clinically appropriate, given their observed cardiorenal and hepatic protective associations.

Source:

Chung MC, et al. (2026, February 2). JAMA Netw Open. SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis. https://pubmed.ncbi.nlm.nih.gov/41729519/